Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

Panelists discuss how when choosing between asciminib and ponatinib for chronic myeloid leukemia treatment, key considerations include the patient’s mutation status, prior tyrosine kinase inhibitor therapy response, cardiovascular risk factors and comorbidities, and the differing safety profiles of the 2 drugs, with ponatinib generally having more cardiovascular concerns but broader mutation coverage vs asciminib’s more favorable tolerability but more specific targeting of BCR::ABL1.

EP: 1.Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

EP: 2.Interpreting Milestones: Prioritizing the Patient Picture

EP: 3.Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

Now Viewing

EP: 4.Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

Video content above is prompted by the following:

• What do you consider when making a treatment decision between asciminib and ponatinib?
• What disease-specific factors do you consider?
• What patient factors do you consider?

Related Videos